Sign In
Buy LQDA
$55.69
+0.580 (+1.05%)
At Close: Jun 03, 2026
-$0.39 Earnings Per Share Expected for Liquidia Technologies Inc (NASDAQ:LQDA) This Quarter
05:30am, Tuesday, 14'th Jul 2020
Equities research analysts expect Liquidia Technologies Inc (NASDAQ:LQDA) to announce earnings of ($0.39) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provi
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating whether the following mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional
Liquidia Announces Closing of Public Offering of Common Stock
08:01pm, Thursday, 02'nd Jul 2020
Liquidia Technologies, Inc. (LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announ
Liquidia Announces Closing of Public Offering of Common Stock
12:00am, Thursday, 02'nd Jul 2020
RESEARCH TRIANGLE PARK, N.C., July 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical...
The following is a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) * ADC Therapeutics SA (NYSE: ADCT) * Altim
Liquidia to Host Conference Call to Provide Update on Recent Announcements
02:45am, Tuesday, 30'th Jun 2020
Liquidia Technologies, Inc. (LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, will h
Liquidia Announces Pricing of Public Offering of Common Stock
02:30am, Tuesday, 30'th Jun 2020
Liquidia Technologies, Inc. (LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announ
Liquidia Announces Proposed Offering of Common Stock
08:05pm, Monday, 29'th Jun 2020
Liquidia Technologies, Inc. (LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announ
Liquidia to Acquire RareGen, LLC, and Expand Presence in PAH
08:01pm, Monday, 29'th Jun 2020
Liquidia Technologies, Inc. (LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announ
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
12:00am, Friday, 26'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 25)
Brainstorm Cell...
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
ACADIA Pharmaceuticals Inc...
Top Stocks To Short As Markets Rebound Ignores Disappointing Monday
12:00am, Tuesday, 23'rd Jun 2020
If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify several To
Cowen & Co. Sticks to Its Buy Rating for Otonomy (OTIC) - Markets
12:47pm, Wednesday, 17'th Jun 2020
In a report issued on June 15, Ken Cacciatore from Cowen & Co. maintained a Buy rating on Otonomy (OTIC
Cowen & Co. Maintains a Buy Rating on IVERIC bio (ISEE) - Markets
12:47pm, Wednesday, 17'th Jun 2020
Cowen & Co. analyst Ken Cacciatore maintained a Buy rating on IVERIC bio (ISEE – Research Report) on June 15
